Q1 2024 Earnings Forecast for Unity Biotechnology, Inc. (NASDAQ:UBX) Issued By HC Wainwright

Unity Biotechnology, Inc. (NASDAQ:UBX) – Research analysts at HC Wainwright issued their Q1 2024 earnings estimates for shares of Unity Biotechnology in a report released on Tuesday, April 16th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of ($0.57) for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Unity Biotechnology’s Q2 2024 earnings at ($0.59) EPS, Q3 2024 earnings at ($0.62) EPS, Q4 2024 earnings at ($0.64) EPS and FY2028 earnings at $0.29 EPS.

Unity Biotechnology Trading Down 1.0 %

NASDAQ UBX opened at $1.51 on Wednesday. The firm’s 50 day simple moving average is $1.66 and its 200 day simple moving average is $1.78. The firm has a market capitalization of $25.25 million, a price-to-earnings ratio of -0.51 and a beta of 0.87. Unity Biotechnology has a 1 year low of $1.50 and a 1 year high of $3.82.

Hedge Funds Weigh In On Unity Biotechnology

A number of institutional investors have recently modified their holdings of the business. Two Sigma Investments LP bought a new position in Unity Biotechnology in the 1st quarter valued at approximately $32,000. Virtu Financial LLC lifted its stake in shares of Unity Biotechnology by 25.4% in the 2nd quarter. Virtu Financial LLC now owns 62,640 shares of the company’s stock valued at $35,000 after acquiring an additional 12,681 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Unity Biotechnology during the 4th quarter valued at $37,000. Schonfeld Strategic Advisors LLC bought a new stake in Unity Biotechnology during the 4th quarter worth $38,000. Finally, Commonwealth Equity Services LLC grew its position in Unity Biotechnology by 53.1% during the 1st quarter. Commonwealth Equity Services LLC now owns 24,512 shares of the company’s stock worth $39,000 after acquiring an additional 8,499 shares during the last quarter. Institutional investors and hedge funds own 29.49% of the company’s stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.